PeopleBio, Inc.

A304840

KR7304840002

Medical Equipment, Supplies & Distribution

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
2,715 ^KRW	0.00%		-1.63%	-11.71%

2023	PeopleBio, Inc. announced that it has received KRW 5.399992647 billion in funding	CI
2023	Peoplebio to Raise 5.4 Billion Won From Shares Issuance	MT

PeopleBio, Inc. announced that it has received KRW 6 billion in funding from UTC Investment Co., Ltd.

November 28, 2021

On November 29, 2021, PeopleBio, Inc. closed the transaction.

Latest news about PeopleBio, Inc.

PeopleBio, Inc. announced that it has received KRW 5.399992647 billion in funding	23-06-28	CI
Peoplebio to Raise 5.4 Billion Won From Shares Issuance	23-06-21	MT
PeopleBio, Inc. announced that it expects to receive KRW 5.399992647 billion in funding	23-06-20	CI
PeopleBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-20	CI
PeopleBio, Inc. announced that it has received KRW 6 billion in funding from UTC Investment Co., Ltd.	21-11-28	CI
PeopleBio, Inc. cancelled the transaction announced on July 1, 2021	21-11-25	CI
PeopleBio, Inc. announced that it expects to receive KRW 19.999988224 billion in funding from UTC Investment Co., Ltd.	21-06-30	CI
PeopleBio, Inc. announced that it expects to receive KRW 37.999966504 billion in funding from Hanyang Securities Co. Ltd., Aju IB Investment Co., Ltd., NH Investment & Securities Co., Ltd., Investment Arm, Nau IB Capital, Investment Arm, Kiwoom Securities Co., Ltd., iMarketKorea Inc. and other investors	21-06-20	CI
PeopleBio, Inc.(KOSDAQ:A304840) added to S&P Global BMI Index	21-03-22	CI
PeopleBio, Inc. has completed an IPO in the amount of KRW 10 billion.	20-10-14	CI
PeopleBio, Inc. has filed an IPO.	20-04-14	CI

PeopleBio Co Ltd is a Korea-based company mainly engaged in the manufacture and sale of medical supplies. The Company's main products include oligomerized beta-amyloid (OAÎ²) test systems, and others. The Companyâs multimer detection system (MDS) is sandwich assay using capturing antibodies and epitope-overlapping detection antibodies for the detection of only oligomers or multimers from monomers in protein-misfolding diseases. The Company sells its products in domestic and overseas markets.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
PEOPLEBIO, INC.	-11.71%	42.15M
BIOMÉRIEUX	-1.89%	12.56B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-9.59%	7.68B
DIASORIN S.P.A.	-1.31%	5.29B
LANTHEUS HOLDINGS, INC.	+21.82%	5.24B
AUTOBIO DIAGNOSTICS CO., LTD.	+0.02%	4.57B
10X GENOMICS, INC.	-50.89%	3.29B
ANDON HEALTH CO., LTD.	+6.42%	2.6B
VITROLIFE AB	-10.02%	2.2B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-8.29%	1.79B